Currently, in the United States and over 40 other countries, every child born is screened for 21-hydroxylase<unk>  at birth. This test detects elevated levels of 17α-hydroxyprogesterone (17-OHP). Detecting high levels of 17-OHP enables early detection of<unk> . Newborns detected early enough can be placed on medication and live relatively normal lives. The screening process, however, is characterized by a high false-positive rate. In one study,<unk>  screening had the lowest positive predictive value (111 true-positive cases among 20,647 abnormal screening results in a 2-year period, or 0.53%, compared with 6.36% for biotinidase deficiency, 1.84% for congenital hypo-thyroidism, 0.56% for classic galactosemia, and 2.9% for phenylketonuria). According to this estimate, 200 unaffected newborns required clinical and laboratory follow-up for every true case of<unk> .
Congenital adrenal hyperplasia
Polycystic ovary syndrome
Lipoid congenital adrenal hyperplasia
Late onset congenital adrenal hyperplasia
Persistent adrenarche syndrome
Congenital iodine deficiency syndrome
Congenital hypothyroidism
Congenital hyperinsulinism